Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Metformin +/- cyclic fasting mimicking diet in combination with platinum-pemetrexed chemotherapy for advanced LKB1 inactive lung adenocarcinoma: The FAME trial.

Galli G, Signorelli D, Vernieri C, Ganzinelli M, Moro M, Fabbri A, Tamborini E, Marabese M, Caiola E, Broggini M, Hollander L, Gallucci R, Gavazzi C, Rizzo AM, Corsetto P, Pruneri G, de Braud F, Sozzi G, Torri V, Garassino MC.

Ann Oncol. 2019 Apr;30 Suppl 2:ii68. doi: 10.1093/annonc/mdz063.086. No abstract available.

2.

EPSILoN score: Validation cohort of a prognostic score in advanced non-small cell lung cancer (aNSCLC) patients treated with immunotherapy.

Prelaj A, Lo Russo G, Signorelli D, Ferrara R, Imbimbo M, Galli G, De Toma A, Randon G, Brambilla M, Trevisan B, Ganzinelli M, Zilembo N, De Braud F, Garassino MC, Proto C.

Ann Oncol. 2019 Apr;30 Suppl 2:ii59. doi: 10.1093/annonc/mdz063.058. No abstract available.

3.

Characterization of patients with metastatic non-small cell lung cancer obtaining long term benefit from immunotherapy.

Galli G, Proto C, Signorelli D, Imbimbo M, Ferrara R, Prelaj A, De Toma A, Randon G, Trevisan B, Ganzinelli M, Zilembo N, Garassino MC, Lo Russo G.

Ann Oncol. 2019 Apr;30 Suppl 2:ii56. doi: 10.1093/annonc/mdz063.048. No abstract available.

4.

Association of Steroids use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.

Petrelli F, Signorelli D, Ghidini M, Ghidini A, Pizzutilo EG, Ruggieri L, Cabiddu M, Borgonovo K, Dognini G, Brighenti M, De Toma A, Rijavec E, Garassino MC, Grossi F, Tomasello G.

Cancers (Basel). 2020 Feb 27;12(3). pii: E546. doi: 10.3390/cancers12030546. Review.

5.

Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohort.

Metro G, Addeo A, Signorelli D, Gili A, Economopoulou P, Roila F, Banna G, De Toma A, Rey Cobo J, Camerini A, Christopoulou A, Lo Russo G, Banini M, Galetta D, Jimenez B, Collazo-Lorduy A, Calles A, Baxevanos P, Linardou H, Kosmidis P, Garassino MC, Mountzios G.

J Thorac Dis. 2019 Dec;11(12):4972-4981. doi: 10.21037/jtd.2019.12.23.

6.

Immune checkpoints inhibitors rechallenge in non-small-cell lung cancer: different scenarios with different solutions?

Metro G, Signorelli D.

Lung Cancer Manag. 2020 Jan 16;8(4):LMT18. doi: 10.2217/lmt-2019-0012. No abstract available.

7.

Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients.

Nichetti F, Ligorio F, Zattarin E, Signorelli D, Prelaj A, Proto C, Galli G, Marra A, Apollonio G, Porcu L, de Braud F, Lo Russo G, Ferrara R, Garassino MC.

Cancers (Basel). 2019 Dec 25;12(1). pii: E67. doi: 10.3390/cancers12010067.

8.

Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program.

Baldini E, Lunghi A, Cortesi E, Turci D, Signorelli D, Stati V, Melotti B, Ricciuti B, Frassoldati A, Romano G, Ceresoli GL, Illiano A, Verderame F, Fasola G, Ricevuto E, Marchetti P, Pinto C, Cartenì G, Scotti V, Tibaldi C, Fioretto L, Giannarelli D.

Lung Cancer. 2020 Feb;140:59-64. doi: 10.1016/j.lungcan.2019.12.014. Epub 2019 Dec 20.

PMID:
31881412
9.

EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort.

Prelaj A, Ferrara R, Rebuzzi SE, Proto C, Signorelli D, Galli G, De Toma A, Randon G, Pagani F, Viscardi G, Brambilla M, Trevisan B, Ganzinelli M, Martinetti A, Gallucci R, Di Mauro RM, Molino G, Zilembo N, Torri V, de Braud FM, Garassino MC, Lo Russo G.

Cancers (Basel). 2019 Dec 5;11(12). pii: E1954. doi: 10.3390/cancers11121954.

10.

Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer.

Landi L, D'Incà F, Gelibter A, Chiari R, Grossi F, Delmonte A, Passaro A, Signorelli D, Gelsomino F, Galetta D, Giannarelli D, Soto Parra H, Minuti G, Tiseo M, Migliorino MR, Cognetti F, Toschi L, Bidoli P, Piantedosi F, Calabro' L, Cappuzzo F.

J Immunother Cancer. 2019 Nov 21;7(1):316. doi: 10.1186/s40425-019-0793-8.

11.

Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer.

Grossi F, Genova C, Crinò L, Delmonte A, Turci D, Signorelli D, Passaro A, Soto Parra H, Catino A, Landi L, Gelsomino F, Tiseo M, Puppo G, Roila F, Ricciardi S, Tonini G, Cognetti F, Toschi L, Tassinari D, Scoppola A, Giannarelli D, Cortesi E.

Eur J Cancer. 2019 Dec;123:72-80. doi: 10.1016/j.ejca.2019.09.011. Epub 2019 Oct 28.

PMID:
31671314
12.

Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer.

Galli G, De Toma A, Pagani F, Randon G, Trevisan B, Prelaj A, Ferrara R, Proto C, Signorelli D, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, Lo Russo G.

Lung Cancer. 2019 Nov;137:38-42. doi: 10.1016/j.lungcan.2019.08.030. Epub 2019 Sep 10.

13.

Unusual skin toxicity associated with sustained disease response induced by nivolumab in a patient with non-small cell lung cancer.

Galli G, Proto C, Cossa M, Valeri B, Sdao S, Signorelli D, Imbimbo M, de Braud F, Garassino MC, Lo Russo G.

Tumori. 2019 Dec;105(6):NP57-NP62. doi: 10.1177/0300891619872546. Epub 2019 Aug 28.

14.

The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma.

Proto C, Signorelli D, Mallone S, Prelaj A, Lo Russo G, Imbimbo M, Galli G, Ferrara R, Ganzinelli M, Leuzzi G, Greco FG, Calareso G, Botta L, Gatta G, Garassino M, Trama A.

Clin Lung Cancer. 2019 Nov;20(6):e652-e660. doi: 10.1016/j.cllc.2019.06.019. Epub 2019 Jun 26.

PMID:
31377142
15.

Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy.

Galli G, Proto C, Signorelli D, Imbimbo M, Ferrara R, Prelaj A, De Toma A, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, Lo Russo G.

Future Oncol. 2019 Aug;15(23):2743-2757. doi: 10.2217/fon-2019-0055. Epub 2019 Jul 24.

PMID:
31339060
16.

Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.

Signorelli D, Giannatempo P, Grazia G, Aiello MM, Bertolini F, Mirabile A, Buti S, Vasile E, Scotti V, Pisapia P, Cona MS, Rolfo C, Malapelle U; Immune-Oncology YOUNG Group.

Biomed Res Int. 2019 Apr 24;2019:9056417. doi: 10.1155/2019/9056417. eCollection 2019. Review.

17.

Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer.

Galli G, Triulzi T, Proto C, Signorelli D, Imbimbo M, Poggi M, Fucà G, Ganzinelli M, Vitali M, Palmieri D, Tessari A, de Braud F, Garassino MC, Colombo MP, Lo Russo G.

Lung Cancer. 2019 Jun;132:72-78. doi: 10.1016/j.lungcan.2019.04.008. Epub 2019 Apr 8.

18.

Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial.

Platania M, Pasini F, Porcu L, Boeri M, Verderame F, Modena Y, Del Conte A, Nichetti F, Garassino MC, Martinetti A, Sottotetti E, Cavanna L, Vattemi E, Pozzessere D, Bertolini A, Irtelli L, Verri C, Sozzi G, Proto C, Pastorino U, Torri V, Fraccon AP, Spinnato F, Signorelli D, Lo Russo G, Tuzi A, Gallucci R, Cinieri S, Mencoboni M, Antonelli P, Giacomelli L, de Braud F.

Lung Cancer. 2019 Jun;132:17-23. doi: 10.1016/j.lungcan.2019.04.001. Epub 2019 Apr 3.

PMID:
31097088
19.

Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors.

Fucà G, Galli G, Poggi M, Lo Russo G, Proto C, Imbimbo M, Ferrara R, Zilembo N, Ganzinelli M, Sica A, Torri V, Colombo MP, Vernieri C, Balsari A, de Braud F, Garassino MC, Signorelli D.

ESMO Open. 2019 Feb 27;4(1):e000457. doi: 10.1136/esmoopen-2018-000457. eCollection 2019.

20.

Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out.

Proto C, Ferrara R, Signorelli D, Lo Russo G, Galli G, Imbimbo M, Prelaj A, Zilembo N, Ganzinelli M, Pallavicini LM, De Simone I, Colombo MP, Sica A, Torri V, Garassino MC.

Cancer Treat Rev. 2019 May;75:39-51. doi: 10.1016/j.ctrv.2019.03.004. Epub 2019 Mar 28. Review.

21.

Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies.

Cona MS, Lecchi M, Cresta S, Damian S, Del Vecchio M, Necchi A, Poggi MM, Raggi D, Randon G, Ratta R, Signorelli D, Vernieri C, de Braud F, Verderio P, Di Nicola M.

Cancers (Basel). 2019 Feb 14;11(2). pii: E223. doi: 10.3390/cancers11020223.

22.

Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study.

Boeri M, Milione M, Proto C, Signorelli D, Lo Russo G, Galeone C, Verri C, Mensah M, Centonze G, Martinetti A, Sottotetti E, Pastorino U, Garassino MC, Sozzi G.

Clin Cancer Res. 2019 Apr 1;25(7):2166-2173. doi: 10.1158/1078-0432.CCR-18-1981. Epub 2019 Jan 7.

23.

Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial.

Vernieri C, Signorelli D, Galli G, Ganzinelli M, Moro M, Fabbri A, Tamborini E, Marabese M, Caiola E, Broggini M, Hollander L, Gallucci R, Vandoni G, Gavazzi C, Triulzi T, Colombo MP, Rizzo AM, Corsetto PA, Pruneri G, de Braud F, Sozzi G, Torri V, Garassino MC.

Clin Lung Cancer. 2019 May;20(3):e413-e417. doi: 10.1016/j.cllc.2018.12.011. Epub 2018 Dec 19.

PMID:
30617039
24.

Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy.

Fucà G, Galli G, Poggi M, Lo Russo G, Proto C, Imbimbo M, Vitali M, Ganzinelli M, Lanti C, Molino G, Stangoni F, Zilembo N, de Braud F, Garassino MC, Signorelli D.

Target Oncol. 2018 Dec;13(6):795-800. doi: 10.1007/s11523-018-0599-5.

PMID:
30306460
25.

Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade.

Lo Russo G, Moro M, Sommariva M, Cancila V, Boeri M, Centonze G, Ferro S, Ganzinelli M, Gasparini P, Huber V, Milione M, Porcu L, Proto C, Pruneri G, Signorelli D, Sangaletti S, Sfondrini L, Storti C, Tassi E, Bardelli A, Marsoni S, Torri V, Tripodo C, Colombo MP, Anichini A, Rivoltini L, Balsari A, Sozzi G, Garassino MC.

Clin Cancer Res. 2019 Feb 1;25(3):989-999. doi: 10.1158/1078-0432.CCR-18-1390. Epub 2018 Sep 11.

26.

Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature review.

Galli G, Corrao G, Imbimbo M, Proto C, Signorelli D, Ganzinelli M, Zilembo N, Vitali M, de Braud F, Garassino MC, Lo Russo G.

Lung Cancer. 2018 Jan;115:135-142. doi: 10.1016/j.lungcan.2017.12.002. Epub 2017 Dec 5. Review.

PMID:
29290256
27.

Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases.

Lo Russo G, Imbimbo M, Corrao G, Proto C, Signorelli D, Vitali M, Ganzinelli M, Botta L, Zilembo N, de Braud F, Garassino MC.

Oncotarget. 2017 Apr 26;8(35):59889-59900. doi: 10.18632/oncotarget.17431. eCollection 2017 Aug 29. Review.

28.

Cognitive impairment and chemotherapy: a brief overview.

Vitali M, Ripamonti CI, Roila F, Proto C, Signorelli D, Imbimbo M, Corrao G, Brissa A, Rosaria G, de Braud F, Garassino MC, Lo Russo G.

Crit Rev Oncol Hematol. 2017 Oct;118:7-14. doi: 10.1016/j.critrevonc.2017.08.001. Epub 2017 Aug 14. Review.

PMID:
28917271
29.

Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future.

Proto C, Imbimbo M, Gallucci R, Brissa A, Signorelli D, Vitali M, Macerelli M, Corrao G, Ganzinelli M, Greco FG, Garassino MC, Lo Russo G.

Transl Lung Cancer Res. 2016 Dec;5(6):563-578. doi: 10.21037/tlcr.2016.10.16. Review.

30.

Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.

Lo Russo G, Pusceddu S, Prinzi N, Imbimbo M, Proto C, Signorelli D, Vitali M, Ganzinelli M, Maccauro M, Buzzoni R, Seregni E, de Braud F, Garassino MC.

Tumour Biol. 2016 Oct;37(10):12991-13003. Epub 2016 Jul 27. Review.

PMID:
27460087
31.

Treatment of Metastatic Colorectal Cancer Patients ≥75 Years Old in Clinical Practice: A Multicenter Analysis.

Grande R, Natoli C, Ciancola F, Gemma D, Pellegrino A, Pavese I, Garufi C, Di Lauro L, Corsi D, Signorelli D, Sperduti I, Cortese G, Risi E, Morano F, Sergi D, Signorelli C, Ruggeri EM, Zampa G, Russano M, Gamucci T.

PLoS One. 2016 Jul 21;11(7):e0157751. doi: 10.1371/journal.pone.0157751. eCollection 2016.

32.

Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem.

Lo Russo G, Macerelli M, Platania M, Zilembo N, Vitali M, Signorelli D, Proto C, Ganzinelli M, Gallucci R, Agustoni F, Fasola G, de Braud F, Garassino MC.

Curr Drug Targets. 2017;18(3):341-362. doi: 10.2174/1389450117666160502152331. Review.

PMID:
27138756
33.

Treatment of lung large cell neuroendocrine carcinoma.

Lo Russo G, Pusceddu S, Proto C, Macerelli M, Signorelli D, Vitali M, Ganzinelli M, Gallucci R, Zilembo N, Platania M, Buzzoni R, de Braud F, Garassino MC.

Tumour Biol. 2016 Jun;37(6):7047-57. doi: 10.1007/s13277-016-5003-4. Epub 2016 Mar 4. Review.

PMID:
26943800
34.

Diagnosis and management of typical and atypical lung carcinoids.

Pusceddu S, Lo Russo G, Macerelli M, Proto C, Vitali M, Signorelli D, Ganzinelli M, Scanagatta P, Duranti L, Trama A, Buzzoni R, Pelosi G, Pastorino U, de Braud F, Garassino MC.

Crit Rev Oncol Hematol. 2016 Apr;100:167-76. doi: 10.1016/j.critrevonc.2016.02.009. Epub 2016 Feb 18. Review.

PMID:
26917456
35.

Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?

Signorelli D, Macerelli M, Proto C, Vitali M, Cona MS, Agustoni F, Zilembo N, Platania M, Trama A, Gallucci R, Ganzinelli M, Pelosi G, Pastorino U, de Braud F, Garassino MC, Lo Russo G.

Tumori. 2016 Jan-Feb;102(1):18-30. doi: 10.5301/tj.5000436. Epub 2015 Oct 14. Review.

PMID:
26481865
36.

Predictive Role of ERCC1 Expression in Head and Neck Squamous Cell Carcinoma Patients Treated with Surgery and Adjuvant Cisplatin-Based Chemoradiation.

Ciaparrone M, Caspiani O, Bicciolo G, Signorelli D, Simonelli I, de Campora L, Mazzarella G, Mecozzi A, Pianelli C, Camaioni A, Catalano P, Pasqualetti P, Fabiano A, Radici M, Marmiroli L, Corsi DC.

Oncology. 2015;89(4):227-34. doi: 10.1159/000430447. Epub 2015 Jun 9.

PMID:
26066774
37.

Cardiac metastasis from renal cell carcinoma successfully treated with pazopanib: impact of TKIs' antiangiogenic activity.

Schinzari G, Monterisi S, Signorelli D, Cona MS, Cassano A, Danza F, Barone C.

Tumori. 2014 Nov-Dec;100(6):e298-300. doi: 10.1700/1778.19304.

PMID:
25688515
38.

Neoadjuvant multidrug chemotherapy including high-dose methotrexate modifies VEGF expression in osteosarcoma: an immunohistochemical analysis.

Rossi B, Schinzari G, Maccauro G, Scaramuzzo L, Signorelli D, Rosa MA, Fabbriciani C, Carlo B.

BMC Musculoskelet Disord. 2010 Feb 16;11:34. doi: 10.1186/1471-2474-11-34.

39.

Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation.

Robinson JP, VanBrocklin MW, Guilbeault AR, Signorelli DL, Brandner S, Holmen SL.

Oncogene. 2010 Jan 21;29(3):335-44. doi: 10.1038/onc.2009.333. Epub 2009 Oct 26.

40.

Menopause not aldosterone-to-renin ratio predicts blood pressure response to a mineralocorticoid receptor antagonist in primary care hypertensive patients.

Olivieri O, Pizzolo F, Ciacciarelli A, Corrocher R, Signorelli D, Falcone S, Blengio GS.

Am J Hypertens. 2008 Sep;21(9):976-82. doi: 10.1038/ajh.2008.234. Epub 2008 Jul 3.

PMID:
18600211
41.

Aldosterone to Renin ratio in a primary care setting: the Bussolengo study.

Olivieri O, Ciacciarelli A, Signorelli D, Pizzolo F, Guarini P, Pavan C, Corgnati A, Falcone S, Corrocher R, Micchi A, Cressoni C, Blengio G.

J Clin Endocrinol Metab. 2004 Sep;89(9):4221-6.

PMID:
15356010
42.

[Survey of physical activity and doping in a sample of 6,915 students aged 14-18 years].

Bassoli L, Boncinelli S, Brizzi L, Curci R, Signorelli D, Pazardjiklian I, Pellai A.

Minerva Pediatr. 2004 Jun;56(3):317-26. Italian.

43.

Psychopharmacology: underuse of evidence-based treatments in psychiatry.

Fayek M, Flowers C, Signorelli D, Simpson G.

Psychiatr Serv. 2003 Nov;54(11):1453-4, 1456. No abstract available.

PMID:
14600298
44.

Epidemiology and prevention of domestic injuries among children in the Verona area (north-east Italy).

Majori S, Bonizzato G, Signorelli D, Lacquaniti S, Andreetta L, Baldo V.

Ann Ig. 2002 Nov-Dec;14(6):495-502.

PMID:
12638353
45.

A new questionnaire for the repeat of the first stage of the European Community Respiratory Health Survey: a pilot study.

de Marco R, Zanolin ME, Accordini S, Signorelli D, Marinoni A, Bugiani M, Lo Cascio V, Woods R, Burney P.

Eur Respir J. 1999 Nov;14(5):1044-8.

46.

Epidemiology of HIV and AIDS. A retrospective look.

Signorelli D, Joseph RJ 2nd.

Clin Podiatr Med Surg. 1998 Apr;15(2):179-87. Review.

PMID:
9576048
47.

Absent end diastolic flow of umbilical artery Doppler: pregnancy outcome in 62 cases.

Poulain P, Palaric JC, Milon J, Betremieux P, Proudhon JF, Signorelli D, Grall JY, Giraud JR.

Eur J Obstet Gynecol Reprod Biol. 1994 Feb;53(2):115-9.

PMID:
8194646
48.

Supplemental Content

Loading ...
Support Center